|
1
|
Induced hypothermia as a new approach to lung rest for the acutely injured lung.
|
Crit Care Med
|
2005
|
2.17
|
|
2
|
Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.
|
Am J Respir Crit Care Med
|
2005
|
1.77
|
|
3
|
Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
|
J Antimicrob Chemother
|
2006
|
1.61
|
|
4
|
Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis?
|
Chest
|
2007
|
1.53
|
|
5
|
Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis.
|
Chest
|
2007
|
1.40
|
|
6
|
Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia.
|
Eur J Cardiothorac Surg
|
2007
|
1.26
|
|
7
|
Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis.
|
Cancer Res
|
2005
|
1.24
|
|
8
|
Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer.
|
Radiat Oncol J
|
2012
|
1.16
|
|
9
|
The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia.
|
Sarcoidosis Vasc Diffuse Lung Dis
|
2002
|
1.11
|
|
10
|
Diagnostic utility of the soluble triggering receptor expressed on myeloid cells-1 in bronchoalveolar lavage fluid from patients with bilateral lung infiltrates.
|
Crit Care
|
2008
|
1.08
|
|
11
|
Long-term effect of bronchial artery embolization in Korean patients with haemoptysis.
|
Respirology
|
2006
|
1.02
|
|
12
|
Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
|
Antioxid Redox Signal
|
2011
|
1.01
|
|
13
|
Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients.
|
Oncol Lett
|
2012
|
0.93
|
|
14
|
Role of Galpha12 and Galpha13 as novel switches for the activity of Nrf2, a key antioxidative transcription factor.
|
Mol Cell Biol
|
2007
|
0.87
|
|
15
|
The clinical efficacy of GOCA scoring system in patients with acute respiratory distress syndrome.
|
J Korean Med Sci
|
2008
|
0.80
|
|
16
|
Melatonin exerts differential actions on X-ray radiation-induced apoptosis in normal mice splenocytes and Jurkat leukemia cells.
|
J Pineal Res
|
2009
|
0.80
|
|
17
|
G alpha 12/13 basally regulates p53 through Mdm4 expression.
|
Mol Cancer Res
|
2007
|
0.79
|
|
18
|
Concurrent Etoposide/Cisplatin Combination Chemotherapy (EP) and Thoracic Radiotherapy after Two Cycles of EP for Limited Stage Small Cell Lung Cancer.
|
Cancer Res Treat
|
2002
|
0.78
|
|
19
|
Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer.
|
Cancer Res Treat
|
2003
|
0.77
|
|
20
|
Adequately washed bronchoscope does not induce false-positive amplification tests on bronchial aspirates in the diagnosis of pulmonary tuberculosis.
|
Chest
|
2002
|
0.77
|
|
21
|
Recovery from lung injury in survivors of acute respiratory distress syndrome: difference between pulmonary and extrapulmonary subtypes.
|
Intensive Care Med
|
2004
|
0.76
|
|
22
|
Hypoxemia and arrhythmia during daily activities and six-minute walk test in fibrotic interstitial lung diseases.
|
J Korean Med Sci
|
2011
|
0.75
|
|
23
|
Is hypercapnea a predictor of better survival in the patients who underwent mechanical ventilation for chronic obstructive pulmonary disease (COPD)?
|
Korean J Intern Med
|
2006
|
0.75
|
|
24
|
Retracted
Inhibition of LXRα-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation.
|
Antioxid Redox Signal
|
2010
|
0.75
|
|
25
|
5-Fluorouracil and Cisplatin (FP) with Concurrent Radiotherapy for Locally Advanced Head and Neck Cancer.
|
Cancer Res Treat
|
2002
|
0.75
|
|
26
|
Preliminary Results of Paclitaxel, Cisplatin and Concurrent High-Dose Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
|
Cancer Res Treat
|
2002
|
0.75
|
|
27
|
Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer.
|
Lung Cancer
|
2003
|
0.75
|
|
28
|
Clinical validation of the lower limit of normal in lung diffusing capacity: is the lower 5th percentile really the best cut-off value?
|
Respir Physiol Neurobiol
|
2009
|
0.75
|